Immunovant, Inc. $IMVT Shares Acquired by GSA Capital Partners LLP

GSA Capital Partners LLP grew its stake in Immunovant, Inc. (NASDAQ:IMVT) by 62.6% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 44,140 shares of the company’s stock after purchasing an additional 16,992 shares during the period. GSA Capital Partners LLP’s holdings in Immunovant were worth $1,122,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the stock. Deep Track Capital LP boosted its holdings in shares of Immunovant by 2.4% in the 3rd quarter. Deep Track Capital LP now owns 9,728,845 shares of the company’s stock valued at $156,829,000 after buying an additional 228,845 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Immunovant by 14.0% in the 4th quarter. Vanguard Group Inc. now owns 7,779,314 shares of the company’s stock valued at $197,750,000 after buying an additional 952,504 shares in the last quarter. Armistice Capital LLC boosted its holdings in shares of Immunovant by 12.2% in the 3rd quarter. Armistice Capital LLC now owns 5,836,000 shares of the company’s stock valued at $94,076,000 after buying an additional 636,000 shares in the last quarter. Two Seas Capital LP boosted its holdings in shares of Immunovant by 22.6% in the 3rd quarter. Two Seas Capital LP now owns 2,762,040 shares of the company’s stock valued at $44,524,000 after buying an additional 509,268 shares in the last quarter. Finally, Alpine Global Management LLC boosted its holdings in shares of Immunovant by 4.9% in the 3rd quarter. Alpine Global Management LLC now owns 2,754,731 shares of the company’s stock valued at $44,406,000 after buying an additional 128,039 shares in the last quarter. Institutional investors and hedge funds own 47.08% of the company’s stock.

Insider Activity

In related news, CTO Jay S. Stout sold 2,754 shares of the stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $29.62, for a total transaction of $81,573.48. Following the completion of the sale, the chief technology officer owned 251,685 shares in the company, valued at $7,454,909.70. This represents a 1.08% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, COO Melanie Gloria sold 8,722 shares of the stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $24.83, for a total transaction of $216,567.26. Following the sale, the chief operating officer owned 245,222 shares of the company’s stock, valued at approximately $6,088,862.26. This represents a 3.43% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 78,141 shares of company stock worth $2,115,713 over the last 90 days. 1.80% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on IMVT shares. Guggenheim upped their target price on shares of Immunovant from $41.00 to $44.00 and gave the company a “buy” rating in a report on Monday, February 9th. The Goldman Sachs Group upped their target price on shares of Immunovant from $29.00 to $32.00 and gave the company a “neutral” rating in a report on Wednesday, April 15th. Citigroup restated a “buy” rating on shares of Immunovant in a report on Thursday. HC Wainwright upped their target price on shares of Immunovant from $35.00 to $40.00 and gave the company a “buy” rating in a report on Thursday. Finally, Sanford C. Bernstein initiated coverage on shares of Immunovant in a research note on Friday, March 20th. They set a “market perform” rating and a $28.00 price target for the company. Six analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Immunovant currently has a consensus rating of “Hold” and an average price target of $34.44.

Immunovant Price Performance

Shares of NASDAQ:IMVT opened at $34.13 on Friday. The stock has a market cap of $6.95 billion, a P/E ratio of -12.28 and a beta of 0.70. The firm has a fifty day moving average price of $26.65 and a 200 day moving average price of $25.85. Immunovant, Inc. has a 1-year low of $13.79 and a 1-year high of $36.28.

Immunovant (NASDAQ:IMVT) last issued its quarterly earnings results on Wednesday, May 20th. The company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.13). During the same period in the previous year, the business posted ($0.64) EPS. Sell-side analysts expect that Immunovant, Inc. will post -2.6 EPS for the current fiscal year.

Key Immunovant News

Here are the key news stories impacting Immunovant this week:

• Positive Sentiment: Immunovant reported strong Phase 2 rheumatoid arthritis data for IMVT-1402, with ACR20/50/70 response rates of 72.7%, 54.5%, and 35.8%, respectively, fueling optimism about the drug’s efficacy. Article Title
• Positive Sentiment: Roivant-backed coverage highlighted the results as a validation of the broader investment case, suggesting the clinical win could support value creation across Immunovant’s autoimmune pipeline. Article Title
• Positive Sentiment: Management also said the cutaneous lupus proof-of-concept trial is fully enrolled, with topline data expected in the second half of 2026, giving investors another potential catalyst. Article Title
• Positive Sentiment: The company reported a strong cash position of about $902 million as of March 31, which should help fund development and extend runway toward a possible future launch. Article Title
• Neutral Sentiment: The quarterly loss was wider than expected, with EPS of -$0.73 versus estimates for -$0.60, but investors appear to be focusing more on the clinical readout than the earnings miss. Article Title
• Negative Sentiment: Director Atul Pande sold 6,000 shares in a pre-arranged Rule 10b5-1 transaction, which may slightly weigh on sentiment even though the sale was planned in advance. Article Title

Immunovant Profile

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.